Effects of Pravastatin on Superoxide and Fibronectin Production of Mesangial Cells Induced by Low-Density Lipoprotein

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Pravastatin is a potent inhibitor of HMG-CoA reductase and is effective in lowering serum lipid levels. Recent studies have shown that pravastatin also reduces the oxidative modification of low-density lipoprotein (LDL). To determine whether pravastatin has a direct effect on glomerular mesangial cells, we have measured the effects of pravastatin on the production of superoxide and fibronectin of glomerular mesangial cells stimulated by LDL. Our results demonstrated that the superoxide production of mesangial cells increased after LDL stimulation (100 µg/ml for 4 h) and that the superoxide production was significantly suppressed by either superoxide dismutase (SOD; 500 U/ml for 36 h; p < 0.01) or pravastatin (80 µ M for 36 h; p < 0.05). The production of fibronectin was also increased after LDL stimulation which was also significantly suppressed by either SOD (p < 0.01) or pravastatin (p < 0.01). SOD or pravastatin alone had no effect on the unstimulated cells. Our results indicate that pravastatin may have a direct effect as an antioxidant and suppresses the fibronectin synthesis of glomerular mesangial cells independent of its hypolipidemic effect.

Related collections

Most cited references 1

Record: found
Abstract: not found
Article: not found

Comparing antiepileptic drugs

RichardH. Mattson (1995)

0 comments Cited 3 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (publisher-id): KBR

Journal ID (nlm-ta): Kidney Blood Press Res

Journal ID (doi): 10.1159/issn.1420-4096

Title: Kidney and Blood Pressure Research

Publisher: S. Karger AG

ISSN (Print): 1420-4096

ISSN (Electronic): 1423-0143

Publication date Subscription-year: 2002

Publication date (Print): 2002

Publication date (Electronic): 06 February 2002

Volume: 25

Issue: 1

Pages: 2-6

Affiliations

^aDepartment of Internal Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; ^bDepartment of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan

Article

Publisher ID: 49428 Other ID: Kidney Blood Press Res 2002;25:2–6

DOI: 10.1159/000049428

PubMed ID: 11834870

SO-VID: e65ccda3-7174-491d-b825-904f175ee2d3

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.